Astellas breaks off Vibativ partnership withTheravance
This article was originally published in Scrip
Executive Summary
Astellas Pharma, Theravance's partner for its only commercialised drug - the antibiotic Vibativ (telavancin hydrochloride) - has decided to pull out of the collaboration.